Deep Brain Stimulation-fornix

THERAPEUTICS Functional Neuromodulation Ltd DBS-f Procedural Intervention Unknown In March 2007-June 2010, an open-label pilot study of bilateral DBS-f ran at the Toronto Western Hospital. Six volunteers with clinically diagnosed probable AD had electrodes implanted a

Ladostigil

THERAPEUTICS Avraham Pharmaceuticals Ltd Ladostigil hemitartrate TV3326 Small Molecule Cholinergic System In 2011 and 2012, Avraham Pharmaceuticals evaluated a six-month course of escalating doses of up to 80 mg twice daily of ladostigil in a Phase 2 study of 201 peop

Masitinib

THERAPEUTICS AB Science Masivet Kinavet AB1010 Masitinib mesylate Small Molecule Other From 2006 to 2009, AB Science conducted a Phase 2 trial comparing 3 and 6 mg/kg/day of masitinib or placebo, taken twice daily for six months as an add-on therapy to cholinesterase

Gantenerumab

THERAPEUTICS Chugai Pharmaceutical Co., Ltd. Hoffmann-La Roche RO4909832 RG1450 R1450 Immunotherapy (passive) Amyloid-Related Four Phase 1 trials conducted internationally in a total of 308 patients have tested the safety, tolerability, pharmacokinetics, and pharmacod

Leqembi

THERAPEUTICS BioArctic AB Biogen Eisai Co., Ltd. Lecanemab-irmb BAN2401 mAb158 Immunotherapy (passive) Amyloid-Related A multicenter Phase 1 trial tested the safety, tolerability, and pharmacokinetics of single and multiple ascending intravenous doses of BAN2401 in 80

Verubecestat

THERAPEUTICS Merck MK-8931, MK-8931-009 BACE inhibitor Small Molecule Amyloid-Related Phase 1 included four public studies of a total of 68 healthy controls, patients with mild to moderate Alzheimer's disease, and people with renal insufficiency, held in Japan an

Riluzole

THERAPEUTICS 6-trifluoromethoxy-2-benzothiazolamine Sanofi Rilutek® RP 54274 Small Molecule Other Neurotransmitters Other Riluzole was approved for ALS because in several clinical trials it modestly extended survival or time to insertion of a breathing tube. Initial c

PAPER De Graeve S, Marinelli S, Stolz F, Hendrix J, Vandamme J, Engelborghs Y, Van Dijck P, Thevelein JM

Mammalian ribosomal and chaperone protein RPS3A counteracts alpha-Synuclein aggregation and toxicity in a yeast model system.

Biochem J. 2013 Aug 7; PubMed: 23924367

PAPER Rey NL, Petit GH, Bousset L, Melki R, Brundin P

Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice.

Acta Neuropathol. 2013 Oct;126(4):555-73. PubMed: 23925565

PAPER Tanner CM

Alpha-synuclein: One key opens many locks.

Mov Disord. 2013 Aug;28(9):1176-8. PubMed: 23925937

PAPER Kern JK, Geier DA, Sykes LK, Geier MR

Evidence of neurodegeneration in autism spectrum disorder.

Transl Neurodegener. 2013;2(1):17. PubMed: 23925007

PAPER Labandeira-Garcia JL, Rodriguez-Pallares J, Dominguez-Meijide A, Valenzuela R, Villar-Cheda B, Rodríguez-Perez AI

Dopamine-Angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease.

Mov Disord. 2013 Sep;28(10):1337-42. PubMed: 23925977

PAPER Cava E, Fontana L

Will calorie restriction work in humans?

Aging (Albany NY). 2013 Jul;5(7):507-14. PubMed: 23924667

PAPER Fujioka Y, Ishigaki S, Masuda A, Iguchi Y, Udagawa T, Watanabe H, Katsuno M, Ohno K, Sobue G

FUS-regulated region- and cell-type-specific transcriptome is associated with cell selectivity in ALS/FTLD.

Sci Rep. 2013;3:2388. PubMed: 23925123

PAPER Palombo DJ, Amaral RS, Olsen RK, Müller DJ, Todd RM, Anderson AK, Levine B

KIBRA Polymorphism Is Associated with Individual Differences in Hippocampal Subregions: Evidence from Anatomical Segmentation using High-Resolution MRI.

J Neurosci. 2013 Aug 7;33(32):13088-93. PubMed: 23926262